

Remit of the AstraZeneca Science Committee

AstraZeneca PLC (the “Company”)

It was resolved to appoint a committee, pursuant to Article 101 of the Articles of Association of the Company, to be known as the Science Committee consisting of not less than two of the Non-Executive Directors of the Company, the Executive Director Development and the Executive Vice President, Discovery. Members of the Committee shall be appointed from time to time by the Board of the Company.

The remit of the Committee shall be:

(i) to provide assurance to the Board regarding the quality, integrity and competitiveness of AstraZeneca’s science based research and development activities. The Committee will aim to assure itself that the approaches and targets adopted throughout the R&D organisation are competitive and an appropriate use of shareholder funds, but it will not be expected to review individual research or licensing projects;

(ii) to consider reports from or join any meeting with any relevant external advisory board when AstraZeneca is considering entry into new areas of science or medicine; (iii) to review, from time to time, together with other external experts important bioethical issues faced by AstraZeneca and to assist in the formulation of, and to agree on behalf of the Board, appropriate policies in relation to such issues; and

(iv) to consider with external experts, from time to time, future trends in medical science and technology.

The members of the Committee will be expected to have a knowledge of, or interest in, life sciences. The Chairman of the Committee shall be nominated by the Board. The Head of Discovery Project Evaluation Group will act as Secretary of the Committee and the quorum for the Committee shall be three. Minutes will be circulated to all Directors and reports of meetings will be given to the Board.

The current members of the Committee are:

Dame Nancy Rothwell, Chair
Bo Angelin
Dr. Jane Henney
Dr. John Patterson
Dr. Christopher Reilly, Secretary

January 08